Search

Displaying results 3531 - 3540 of 8697 in total
  1. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    If this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD. … Unlike currently marketed AChE inhibitors, it has a dual mechanism of action that also includes anti-amyloid activity, which may confer disease-modifying effects in patients with AD.

  2. Drug

    Raseglurant

    go.drugbank.com/drugs/DB05070
    Investigational

    The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety. … ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).

  3. Drug

    Thonzonium

    go.drugbank.com/drugs/DB09552
    Approved

    It is also reported that thonzonium also confers an antifungal property and antiresorptive effect on bone. … It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication.

  4. Drug

    Albendazole

    go.drugbank.com/drugs/DB00518
    ApprovedInvestigationalVet approved

    A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  5. Drug

    Cloxazolam

    go.drugbank.com/drugs/DB01553
    Experimental

    As well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness. … The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety.

  6. Drug

    AT9283

    go.drugbank.com/drugs/DB05169
    Investigational

    AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer.

  7. Drug

    Rebamipide

    go.drugbank.com/drugs/DB11656
    ApprovedInvestigational

    Rebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  8. Drug

    Fexapotide

    go.drugbank.com/drugs/DB05493
    Investigational

    NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. … Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).

  9. Drug

    Otenabant

    go.drugbank.com/drugs/DB11745
    Investigational

    Otenabant has been investigated for the treatment of Obesity.

    Categories: Cannabinoid Receptor Antagonists, Receptor, Cannabinoid, CB1, antagonists & inhibitors
  10. Drug

    Polycarbophil

    go.drugbank.com/drugs/DB09311
    ApprovedWithdrawn

    This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea. … Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali.